

ASX Announcement

12 June 2026

OncoSil Medical Launches Investor Hub for Enhanced Shareholder Engagement

Catalyst-Rich Second Half of 2026 Anticipated

Sydney, Australia – 12 June 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the launch of the Company’s new Investor Hub, which will provide existing and prospective shareholders with real-time access to ASX announcements, reports, presentations, videos and direct engagement with the OncoSil Medical team.

Shareholders and interested parties are encouraged to sign up and create an account.

Investor Hub Sign Up

- Visit: <https://investors.oncosil.com/auth/signup>
- Follow the prompts to create an account
- Complete your account profile

The Investor Hub launch comes as OncoSil Medical enters what the Board considers to be one of the most important periods in the Company’s development. Following on from the recent TGA approval of the OncoSil™ device in Australia, progress with the Company’s HDE application with the US FDA and results of the TRIPP-FFX clinical trial, there will be a cadence of further manufacturing, clinical, regulatory and commercial milestones anticipated across the remainder of 2026. Accordingly, the Company is committed to ensuring that every shareholder, retail and institutional alike, has timely access to the same information and a direct channel through which to engage with the Company.

[Click here](#) to leave a question about this announcement, to view our introductory video and to visit our Investor Hub.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703
---	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year². Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Australia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>